230 related articles for article (PubMed ID: 21431900)
1. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease.
Tokiwa S; Muto S; China T; Horie S
Clin Exp Nephrol; 2011 Aug; 15(4):539-45. PubMed ID: 21431900
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
3. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
6. Kidney volume and function in autosomal dominant polycystic kidney disease.
Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
[TBL] [Abstract][Full Text] [Related]
8. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
9. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; You Z; Gitomer B; Brosnahan G; Torres VE; Chapman AB; Perrone RD; Steinman TI; Abebe KZ; Rahbari-Oskoui FF; Yu ASL; Harris PC; Bae KT; Hogan M; Miskulin D; Chonchol M
J Am Soc Nephrol; 2018 Feb; 29(2):571-578. PubMed ID: 29118087
[TBL] [Abstract][Full Text] [Related]
10. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
11. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
12. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.
Fick-Brosnahan GM; Belz MM; McFann KK; Johnson AM; Schrier RW
Am J Kidney Dis; 2002 Jun; 39(6):1127-34. PubMed ID: 12046022
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
Chen D; Ma Y; Wang X; Yu S; Li L; Dai B; Mao Z; Sun L; Xu C; Rong S; Tang M; Zhao H; Liu H; Serra AL; Graf N; Liu S; Wüthrich RP; Mei C
PLoS One; 2014; 9(3):e92232. PubMed ID: 24651850
[TBL] [Abstract][Full Text] [Related]
15. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
16. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
17. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
18. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
[TBL] [Abstract][Full Text] [Related]
19. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
Chen H; Watnick T; Hong SN; Daly B; Li Y; Seliger SL
BMC Nephrol; 2019 Oct; 20(1):386. PubMed ID: 31653199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]